97 related articles for article (PubMed ID: 7716950)
1. [Assessment of hypolipemic action of the preparation olbetam in people with primary hypercholesterolemia].
Miturzyńska-Stryjecka H; Widomska-Czekajska T; Bielak G; Grossmann G
Wiad Lek; 1994 Aug; 47(15-16):566-9. PubMed ID: 7716950
[No Abstract] [Full Text] [Related]
2. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
Yeshurun D; Hamood H; Morad N; Naschitz J
Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
[TBL] [Abstract][Full Text] [Related]
3. [Effect of hypolipemic agents on levels of total plasma homocysteine].
Dvoráková J; Dubská L; Táborský L; Hyánek J
Vnitr Lek; 2001 Oct; 47(10):674-7. PubMed ID: 11789004
[No Abstract] [Full Text] [Related]
4. [What should be the role of antilipemic agents in the control of hypercholesterolemia in elderly persons?].
Champoux N; Latour J
Union Med Can; 1994 Feb; 123(2):91-4. PubMed ID: 8203037
[No Abstract] [Full Text] [Related]
5. [Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes].
Rajecová E; Kréze A; Klimes I; Cvrkalová A; Lacko A; Langrová H; Hanzen E
Cas Lek Cesk; 1991 Nov; 130(22-23):661-3. PubMed ID: 1786587
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)].
Quintão EC; de Castilho LN
Arq Bras Cardiol; 1985 Jan; 44(1):37-40. PubMed ID: 4062591
[No Abstract] [Full Text] [Related]
7. Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
Paragh G; Balogh Z; Boda J; Kovács P; Kárpáti L; Szabó J; Leövey A
Acta Biol Hung; 1997; 48(3):359-67. PubMed ID: 9406614
[TBL] [Abstract][Full Text] [Related]
8. [Hypercholesterolemia and the diagnosis and management of hyper- lipidemia in adults. Recommendations of the working groups of the Finnish Society of Internal Medicine and the Finnish Cardiology Society].
Duodecim; 1988; 104(18):1425-38. PubMed ID: 3181045
[No Abstract] [Full Text] [Related]
9. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002.
Arnett DK; Jacobs DR; Luepker RV; Blackburn H; Armstrong C; Claas SA
Circulation; 2005 Dec; 112(25):3884-91. PubMed ID: 16344385
[TBL] [Abstract][Full Text] [Related]
10. [The lowering of serum cholesterol in the prevention of coronary disease (part 1). The Canadian Study Group for Periodic Medical Examinations].
Union Med Can; 1994 Apr; 123(4):249-58. PubMed ID: 8203048
[No Abstract] [Full Text] [Related]
11. [Necessity of hypolipemic treatment in patients with coronary disease].
Fernández-Miranda C; Aranda IL
Med Clin (Barc); 1999 Mar; 112(11):438. PubMed ID: 10231779
[No Abstract] [Full Text] [Related]
12. Medication for hypercholesterolemia and the risk of nonfatal acute myocardial infarction: case-control study in Japan.
Circ J; 2002 May; 66(5):463-8. PubMed ID: 12030341
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hypercholesterolemia in the elderly].
Mulder WJ; Lavrijssen AT; Wolffenbuttel BH; Fiolet JF
Ned Tijdschr Geneeskd; 1995 Apr; 139(16):821-5. PubMed ID: 7731473
[No Abstract] [Full Text] [Related]
14. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
Ivanova TN; Poliakova ED; Olfer'ev AM; Perova NV
Biull Eksp Biol Med; 1998 May; 125(5):569-73. PubMed ID: 9644562
[No Abstract] [Full Text] [Related]
15. [Hypolipemic treatment in pre- and postmenopausal women].
Ferreira Aguar A; Casasnovas Lenguas JA; Ferreira Montero IJ
Rev Esp Cardiol; 1994; 47 Suppl 3():27-31. PubMed ID: 7816977
[No Abstract] [Full Text] [Related]
16. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
Jover E; Aranda JL; Nogués X; del Palacio A; Rubiés-Prat J
Med Clin (Barc); 1996 May; 106(20):776-9. PubMed ID: 8801396
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and biological study of a new vascular protective agent and hypolipemic agent, pyridoxine para-chloro-phénoxy-isobutyrate. (Claresan)].
Fourrier A; Mouton Y
Lille Med; 1974 Apr; 19(4 Suppl 11):532-7. PubMed ID: 4612283
[No Abstract] [Full Text] [Related]
18. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
Bays H; Rhyne J; Abby S; Lai YL; Jones M
Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
[TBL] [Abstract][Full Text] [Related]
19. [Hypercholesterolemia: when and how much to treat it?].
Carmena R
Med Clin (Barc); 1983 Feb; 80(6):261-2. PubMed ID: 6865558
[No Abstract] [Full Text] [Related]
20. Women with heart disease may need aggressive treatment for high cholesterol.
Int J Fertil Womens Med; 1997; 42(3):182. PubMed ID: 9222800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
